|
Match
|
Document |
Document Title |
|
|
6436407 |
Mutant enterotoxin effective as a non-toxic adjuvant
Methods and compositions are provided herein for the use of a novel mutant form of E. coli heat-labile enterotoxin which has lost its toxicity but has retained its immunologic activity. This...
|
|
|
6432679 |
Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220
The present invention provides vaccine adjuvants comprising the Epstein Barr Virus glycoprotein 350/220 or naturally occurring variants thereof, a fusion protein comprising EBV Gp350/220 sequence...
|
|
|
6429298 |
Assays for identifying functional alterations in the p53 tumor suppressor
The present invention provides for various screening assays which are amenable to high throughput formats and identify a variety of useful mutations in tumor suppressor genes such as p53. Such...
|
|
|
6423320 |
Inhibitor of immunoglobulin E antibody production
A polysaccharide and fragments thereof derived from Klebsiella oxytoca or Klebsiella pneumonia inhibit the IgE antibody production and response and, therefore, are useful in the prophylaxis...
|
|
|
6417341 |
Malaria merozoite antigen subunit vaccine
An immunogenic polypeptide for use in inducing an immune response against Plasmodium infection comprises an amino acid sequence corresponding to a non-full length fragment of the apical membrane...
|
|
|
6416947 |
Vaccine adjuvant and vaccine method
The present invention includes novel polyoxyethylene/polyoxypropylene block copolymers as well as methods for making the block copolymers. The block copolymers are high molecular weight molecules...
|
|
|
6410509 |
Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment
The present invention concerns the use of a MHC class II ligand, LAG-3, for the manufacture of a medicament for preventing or treating pathological conditions involving an antigen specific immune...
|
|
|
6410515 |
Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
A peptide of the formula I X-A-D-Trp-Y wherein X is hydrogen, glycine, alanine, leucine, isoleucine, valine, N-valine, proline, tyrosine, phenylalanine, tryptophan, D-alanine, D-leucine,...
|
|
|
6406861 |
Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration
Methods of reducing pre-existing humoral immunity to a viral immunogenic therapeutic agent such as adenovirus, using immunoapheresis are disclosed. Antibodies specific for the viral immunogenic...
|
|
|
6406705 |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one...
|
|
|
6406698 |
Pharmaceutical composition comprising serum amyloid P component for prophylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components
Pharmaceutical compositions comprising a protein serum amyloid P component (SAP) capable of binding viruses, especially myxovirus, e.g. influenza viruses and thereby preventing the transmission and...
|
|
|
6406699 |
Composition and method of cancer antigen immunotherapy
A cancer immunotherapy method and composition for treating cancer in a patient comprised of vaccinating a patient with a vaccine comprised of the patient's own malignancy and an immunologic...
|
|
|
6399078 |
Chemokine—glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases
The present invention provides therapeutic compositions of receptor ligand-containing antagonist complexes and methods of using them to treat diseases, disorders or conditions associated with the...
|
|
|
6392014 |
Cloning of gene encoding the GP28.5 protein of Toxoplasma gondii; peptide fragments of said protein and their applications
The invention relates to cloning of the gene for the toxoplasma GP28.5 antigen. It also encompasses purified GP28.5 antigen preparations and antigenic polypeptides derived from said antigen, and...
|
|
|
6391570 |
Methods and compositions for the detection of bacterial endotoxins
The invention provides methods and compositions for the detection and/or quantification of bacterial endotoxins. In particular, provided herein is an inexpensive and reproducible method for...
|
|
|
6372227 |
Vaccines
The present invention relates to oil in water emulsion compositions, their use in medicine, in particular to their use in augmenting immune responses to a wide range of antigens, and to methods of...
|
|
|
6361775 |
Compositions and methods for vaccines comprising α-galactosyl epitopes
The invention encompasses methods and compositions for inducing an immune response in an anti-Gal synthesizing animal including viral and tumor antigens manipulated to express α-galactosyl epitopes.
|
|
|
6355414 |
Immunopotentiating formulations for vaccinal use
The present invention is related to the field of medicine, particularly to the use of new adjuvant formulations with vaccine antigens. The technical objective pursued with this invention is,...
|
|
|
6355257 |
Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
Aminoalkyl glucosamine phosphate compounds that are adjuvants and immunoeffectors are described and claimed. The compounds have a 2-deoxy-2-amino glucose in glycosidic linkage with an aminoalkyl...
|
|
|
6355271 |
Therapeutic calcium phosphate particles and methods of manufacture and use
Novel calcium phosphate core particles, methods of making them, and methods of using them as vaccine adjuvants, as cores, as carriers of biologically active material, and as controlled release...
|
|
|
6355256 |
Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
The invention involves the combination of Interleukin-12 with p53 derived peptides and an adjuvant, preferably QS-21. It is found that this combination provokes a surprisingly strong immune...
|
|
|
6352697 |
Saponin preparations and use thereof in iscoms
Saponin preparations based on defined compositions of purified saponin fractions derived from the bark of Quillaja saponaria Molina are disclosed. The saponin preparations are useful in...
|
|
|
6342226 |
Method for increasing immunogenicity, product obtained and pharmaceutical compositions
The present invention relates to a method for increasing the immunogenicity of an antigen, characterized in that the antigen is combined via stable interactions with a particulate vector, said...
|
|
|
6340461 |
Superantigen based methods and compositions for treatment of diseases
The present invention relates to therapeutic methods and compositions employing superantigens. Methods and compositions employing superantigens and immunotherapeutic proteins in combination with...
|
|
|
6340464 |
Adjuvants for vaccines
Vaccine adjuvants comprising a liquid medium contain polymers with anionic constitutive repeating units and hydrophobic constitutive repeating units. Advantageously, the adjuvants are aqueous...
|
|
|
6340463 |
Identification of antigenic peptide sequences
Identification of linear amino acid antigenic sequences for the production of both polyclonal and monoclonal antibodies to defined antigenic domains is described. Also described are antigenic...
|
|
|
6333036 |
Vaccine composition containing polyribosylribitol phosphate and method for making same
Vaccine compositions are disclosed which comprise at least one antigen formed by the capsular polysaccharide of Haemophilus influenzae type b or high molecular weight polyribosylribitol phosphate...
|
|
|
6333038 |
Prophylaxis of allergic disease
The invention provides a method for preventing allergic disease in an individual susceptible to such disease, comprising administering an allergen to which the individual has not been sensitized...
|
|
|
6333028 |
Method of using haptenized ovarian carcinoma tumor cells
The present invention is directed to compositions and methods of treating cancer. The compositions of the present invention include a composition prepared from a tumor cell which is hapten modified...
|
|
|
6331403 |
Use of mCRP to slow cell growth and to promote maturation of cells
The invention provides a method of slowing cell growth and promoting the maturation of cells other than cancer cells and megakaryocyte progenitor cells. The method comprises contacting the cells...
|
|
|
6331388 |
Immune response enhancer
The present invention provides methods for specifically increasing expression of MHC class I molecules in cells, and in particular, in poorly immunogenic tumor cells as well as in pathogen-infected...
|
|
|
6328965 |
Vaccine adjuvants
Vaccine adjuvants comprising a sulpholipid polysaccharide in combination with an interface-forming constituent. The invention also provides a method for preparing a vaccine by emulsifying an...
|
|
|
6328978 |
Methods for the treatment of immunologically-mediated skin disorders
Methods for the treatment of skin disorders, including psoriasis, atopic dermatitis, allergic contact dermatitis, alopecia areata and skin cancers are provided, such methods comprising...
|
|
|
6328971 |
MAGE-1 derived nona peptides, and compositions thereof
This invention relates to MAGE-1 derived nonapeptides. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
|
|
|
6316007 |
Combined physical and immunotherapy for cancer
The present invention combines physical and immunologic therapies for the treatment of neoplasms by conditioning a targeted neoplasm with an immunoadjuvant (also called immuno-modulator or...
|
|
|
6312700 |
Method for enhancing an antigen specific immune response with OX-40L
Compositions and methods for enhancing the immune response of a mammal to an antigen by engaging the OX-40 receptor on the surface of T-cells are disclosed, comprising administering to the mammal a...
|
|
|
6290971 |
Adjuvant compositions comprising a mineral salt and another immunostimulating compound
Adjuvant compositions for modulating an immune response to an antigen administered to a host comprise a mineral salt adjuvant and at least one other adjuvant. The compositions provide an...
|
|
|
6290962 |
Urease-based vaccine and treatment for helicobacter infection
Method of eliciting in a mammalian host a protective immune response to Helicobacter infection and treatment of Helicobacter infection by administering to the host an immunogenically effective...
|
|
|
6290967 |
Stabilizers for lyophilized vaccines
Vaccine stabilizers, vaccine formulations and lyophilized vaccines with enhanced thermostability are disclosed. The vaccine formulations comprise an increased amount of a 6-carbon polyhydric...
|
|
|
6290972 |
Method of augmenting a vaccine response by administering CD40 ligand
There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human...
|
|
|
6281193 |
Compounds that inhibit the binding of RAF-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same
The invention relates to compounds, such as proteins, peptides and organic compounds, capable of blocking or inhibiting the binding interaction of Raf-1 or 14-3-3 proteins to the β chain of IL-2,...
|
|
|
6270957 |
Non-Imuunosuppressive cyclosporins and their use in the prevention and treatment of HIV infection
Disclosed are cyclosporin analogs having amino acid residue substitutions at positions 1, 3, or 7 of the cyclosporin peptide backbone. Also disclosed are conjugates of these cyclosporin analogs in...
|
|
|
6261573 |
Immunoadjuvants
The present invention provides immunogenic compositions and methods for inducing enhanced immune responses using an antigen and a combination of water soluble polymer and an amphiphilic compound.
|
|
|
6258357 |
Inhibition of graft versus host disease
The development of graft versus host disease in a mammalian patient undergoing cell transplantation therapy for treatment of a bone marrow mediated disease, is prevented or alleviated by subjecting...
|
|
|
6255097 |
Two-phase system for the production and presentation of foreign antigens in hybrid live vaccines
The present invention relates to a genetic engineering process for the optimal production and exposure to the immune system of additional antigen coded for by a live vaccine. The genetic...
|
|
|
6255278 |
Composition containing pooled transferrins as an active principle for the induction of immune tolerance against antigens
A method for controlling immune reactions to a foreign tissue or a foreign cell in a recipient host mammal to enhance tolerance of the recipient host mammal towards a grafted foreign tissue or a...
|
|
|
6245752 |
Compositions and methods for tolerization in immune complex-mediated disease progression
Methods and compositions are provided for tolerizing shed antigen-specific B cells involved in an immune complex-mediated disease progression. The composition comprises a substantially...
|
|
|
6241992 |
Bovine footrot treatment and prevention
This invention provides compositions and methods for treating or preventing footrot, in particular bovine footrot, by administering Porphyromonas and/or Prevotella and/or subunits and/or toxins...
|
|
|
6241995 |
Polygala senega compositions and methods of use
Novel Polygala senega saponin pharmaceutical compositions are disclosed. The P. senega saponins are useful as immunological adjuvants to enhance immune responses to a co-administered antigen.
|
|
|
6238670 |
Compositions and methods employing a ligand for CD21 or CD19 for modulating the immune response to an antigen
Described herein are compositions which modulate the immune response. In one aspect, a composition is described which comprises an antigen covalently linked to a ligand for CD21(CR2) or CD19. This...
|